OncoCyte Stock Forum

$OncoCyte (OCX.US)$ Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
9 MINUTES AGO, 6:35 PM EDT
VIA GLOBENEWSWIRE

$OncoCyte (OCX.US)$
Oncocyte Signs Leading Transplant Centers in US and Germany
Oncocyte (Nasdaq: OCX) has announced new agreements with two leading transplant university hospitals in the U.S. and Germany to utilize GraftAssure™, the company's research-use-only assay for detecting early evidence of graft organ damage. This development is part of Oncocyte's strategy to drive commercial adoption of its molecular diagnostic tests in the estimated $1 billion transplant addressable market.
...

$OncoCyte (OCX.US)$
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Oncocyte (Nasdaq: OCX) has announced a $10.2 million private placement of securities priced at-the-market under Nasdaq rules. The company has secured participation from new and existing investors, including strategic partner Bio-Rad Laboratories. The private placement involves the sale of 3,461,138 shares of common stock at $2.948 per share, with certain in...

$OncoCyte (OCX.US)$ waiting patiently

$OncoCyte (OCX.US)$ Its time. Gradually it will go up.

$OncoCyte (OCX.US)$ Buy

$OncoCyte (OCX.US)$
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
On May 30, 2024, Oncocyte announced that favorable results for its VitaGraft Kidney test were published in the New England Journal of Medicine. Data from a phase 2 study indicated that the test could monitor graft injury and identify responses to the investigational drug felzartamab. Results showed significant reductions in donor-derived cell-free DNA (dd-cfDNA) levels at wee...

$OncoCyte (OCX.US)$  Slow and steady move ↗️

$OncoCyte (OCX.US)$ Director Arno Andrew purchased 33,898 shares of common stock on Apr 11, 2024 at an average price of $2.95 for a total value of $99,999.1.

I have noticed recently that some shares despite FDA approval, price action is opposite, also earning call sometimes when it beats estimates projection, the market sentiment or price action is in reverse.
Which is more important when picking a trade:
Earning or FDA outcome
Acquisition or Market sentiment
Happy to learn from friends here.
$Enlivex Therapeutics (ENLV.US)$
$Akebia Therapeutics (AKBA.US)$
$Rekor Systems (REKR.US)$
$OncoCyte (OCX.US)$